prnewswire precigen inc: Live & Latest News Updates : Vimarsana.com

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASC

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Precigen And Recurrent Respiratory Papillomatosis Foundation To Hold Inaugural International RRP Awareness Day On June 11Th

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GERMANTOWN, Md., Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,...

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

– Designation is an important step toward bringing this potentially life-changing therapy to European patients – – EU Orphan Drug Designation is the first regulatory designation for a gorilla...

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Dec. 18, 2023 /PRNewswire/ -- Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,...

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

– Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA...

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

–   FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be required to support submission of a...

Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

–  First FDA Breakthrough Therapy Designation granted for AdenoVerse immunotherapy platform; designation prioritizes PRGN-2012 as a potential treatment for RRP –– ... | June 20, 2023

Precigen Reports First Quarter 2023 Financial Results and Business Updates

– Positive Phase 1 clinical data presented for PRGN-2012 AdenoVerse™ immunotherapy in RRP demonstrated favorable safety profile and significant reduction in...